Big picture - Why invest in HemoGenyx Pharmaceuticals
HemoGenyx Pharmaceuticals Snapshot
Our passionate mission
We believe that we can transform patients' lives by delivering breakthrough therapies.
We also believe that good business means healthy people and a better world.
Develop - To develop new therapies that are based on breakthrough science
Hope - To bring hope to patients with serious or life threatening diseases
Treat - To treat life threatening diseases, bringing soecietal benefit
Value - To realise unique treatment opportunities for patients and value for investors
How it works
BM/HSC transplants includes a number of procedures whereby the BM/HSC of a patient are depleted and then replaced with hematopoietic stem/progenitor cells (HSPC) derived from the patient him/herself (Autologous HSCT) or from a donor (Allogeneic HSCT). Every BM/HSC transplant can be subdivided into three major stages. HemoGenyx's technologies target the first two stages where the greatest risks and limitations are, as shown below. Hemogenyx's technologies are complementary, but can also be used as stand alone products in line with traditional methods.
A Special Class of Cancer Free Cells For Hematopoetic/Bone Marrow Transplantation
HemoGenyx utilizes postnatal human hemogenic endothelial cells (Hu-PHEC cells), discovered by HemoGenyx Co-Founder Dr. Vladislav Sandler, to generate cancer-free hematopoietic stem cells (HSC) for use in transplants to treat blood cancers with superior results.
Hu-PHEC-based technology presents a number of important advantages compared to other existing and developing technologies. Most of these advantages are rooted in the fact that Hu-PHEC are a naturally occurring cell type found in adult and postnatal mammalian tissues. They can easily be isolated and do not require "heavy" manipulation before use. Hu-PHEC are “healthy” because they do not accumulate blood cancer-related mutations and/or chromosomal rearrangements, making them a perfect candidate for autologous (patient-specific) BM/HSC transplantations. In addition, Hu-PHEC can be propagated in vitro, allowing the introduction of therapeutic genes and gene modifications and making them a prime candidate for curative gene therapy applications.
HemoGenyx is developing Hu-PHEC technology based on cells isolated from two different sources:
Hu-PHEC isolated from umbilical cord and placenta:
Cord blood is extracted from the vessels of the umbilical cord and placenta of a donor using standard methods. To isolate endothelial cells emptied blood vessels of the tissues are treated using a proprietary method developed by HemoGenyx.
To isolate Hu-PHEC, endothelial cells are sorted using fluorescent activated cell sorting (FACS) using proprietary FDA certified reagents developed by HemoGenyx utilizing proprietary methods (patent pending; PCT Patent Application No. PCT/US2014/065469). Isolated Hu-PHEC are stored for further use in conjunction with standard cord blood cells for further use in transplantation. When needed, both Hu-PHEC and cord blood cells obtained from the same donor are used for hematopoietic transplantation per existing and widely practiced transplantation protocols.
Hu-PHEC isolated from the liver biopsy of a patient:
A liver biopsy is obtained from a patient per existing and widely practiced protocols. Endothelial cells are isolated from a liver biopsy of a patient using a proprietary method developed by HemoGenyx.
To isolate Hu-PHEC, endothelial cells are sorted using fluorescent activated cell sorting (FACS) using proprietary FDA certified reagents developed by HemoGenyx utilizing proprietary methods (patent pending; PCT Patent Application No. PCT/US2014/065469). Isolated Hu-PHEC are stored for further use in transplantation. When needed, liver Hu-PHEC are activated and intravenously transplanted to the patient they were obtained from.
CDX Bi-specific Antibodies for Patient Conditioning
In order to obviate the use of chemotherapeutic agents for conditioning of patients undergoing BM/HSC transplantations, HemoGenyx developed a method of selective elimination of hematopoietic stem cells/hematopoietic progenitors (HSC/HP) in patients using highly specific CDX antibodies. CDX antibodies belong to a class of bi-specific antibodies that redirect patients’ own immune cells to eliminate HSC. In addition, CDX antibodies show promise in efficiently eliminating malignant cells belonging to a subset of leukemia. In sum, CDX antibodies have the potential to both eliminate malignant leukemic cells and increase the efficiency of conditioning while diminishing the side effects that accompany traditional methods of patient conditioning.
As at 5 October 2017, the number of shares in issue was 356,042,854.
|On the date of Admission|
|Flascherberg Capital Anstalt||27,996,487||7.86|
|43 North LLC||11,371,429||
5 Fleet Place
Optiva Securities Limited
2 Mill Street
Shard Capital Partners LLP
20 Fenchurch Street
RULE 3 ADVISER AND FINANCIAL ADVISER
Peterhouse Corporate Finance Limited
New Liverpool House
15 Eldon Street
AUDITORS AND REPORTING ACCOUNTANTS
PKF Littlejohn LLP
Computershare Investor Services PLC
LEGAL ADVISERS TO THE COMPANY AS TO ENGLISH LAW
Charles Russell Speechlys LLP
5 Fleet Place
LEGAL ADVISERS TO THE COMPANY AS TO US LAW
Rubin & Rudman LLP
50 Rowes Wharf
FINANCIAL PR AND INVESTOR RELATIONS
Walbrook PR Ltd
4 Lombard Street
Tel: 020 7933 8780
Email: [email protected]